Science & Technology
Wed, July 23, 2025
[ Wed, Jul 23rd ]: WESH
[ Wed, Jul 23rd ]: ABC
[ Wed, Jul 23rd ]: Seeking Alpha
[ Wed, Jul 23rd ]: Politico
[ Wed, Jul 23rd ]: yahoo.com
[ Wed, Jul 23rd ]: Atlanta Journal-Constitution
[ Wed, Jul 23rd ]: The Motley Fool
[ Wed, Jul 23rd ]: reuters.com
[ Wed, Jul 23rd ]: Telangana Today
[ Wed, Jul 23rd ]: Fox News
[ Wed, Jul 23rd ]: Newsweek
[ Wed, Jul 23rd ]: Medscape
[ Wed, Jul 23rd ]: The Scotsman
[ Wed, Jul 23rd ]: Deseret News
[ Wed, Jul 23rd ]: Forbes
[ Wed, Jul 23rd ]: KWCH
[ Wed, Jul 23rd ]: ThePrint
[ Wed, Jul 23rd ]: New Jersey Monitor
[ Wed, Jul 23rd ]: moneycontrol.com
[ Wed, Jul 23rd ]: Milwaukee Journal Sentinel
[ Wed, Jul 23rd ]: Daily Express
Tue, July 22, 2025
[ Tue, Jul 22nd ]: Fox 13
[ Tue, Jul 22nd ]: newsbytesapp.com
[ Tue, Jul 22nd ]: CNBC
[ Tue, Jul 22nd ]: Forbes
[ Tue, Jul 22nd ]: The Hill
[ Tue, Jul 22nd ]: KBTX
[ Tue, Jul 22nd ]: Detroit News
[ Tue, Jul 22nd ]: Fox News
[ Tue, Jul 22nd ]: The Independent
[ Tue, Jul 22nd ]: NBC DFW
[ Tue, Jul 22nd ]: Phys.org
[ Tue, Jul 22nd ]: Post-Bulletin, Rochester, Minn.
[ Tue, Jul 22nd ]: STAT
[ Tue, Jul 22nd ]: Associated Press
[ Tue, Jul 22nd ]: Newsweek
[ Tue, Jul 22nd ]: Space.com
[ Tue, Jul 22nd ]: Channel 3000
[ Tue, Jul 22nd ]: Tacoma News Tribune
[ Tue, Jul 22nd ]: The 74
[ Tue, Jul 22nd ]: Orlando Sentinel
[ Tue, Jul 22nd ]: Auburn Citizen
[ Tue, Jul 22nd ]: Impacts
[ Tue, Jul 22nd ]: BBC
Mon, July 21, 2025
[ Mon, Jul 21st ]: AFP
[ Mon, Jul 21st ]: Forbes
[ Mon, Jul 21st ]: ESPN
[ Mon, Jul 21st ]: al.com
[ Mon, Jul 21st ]: WFRV Green Bay
[ Mon, Jul 21st ]: Organic Authority
[ Mon, Jul 21st ]: Fox News
[ Mon, Jul 21st ]: gadgets360
[ Mon, Jul 21st ]: CNN
[ Mon, Jul 21st ]: USA TODAY
[ Mon, Jul 21st ]: NBC New York
[ Mon, Jul 21st ]: CBS News
[ Mon, Jul 21st ]: Seeking Alpha
[ Mon, Jul 21st ]: NJ.com
[ Mon, Jul 21st ]: Reuters
[ Mon, Jul 21st ]: Stateline
[ Mon, Jul 21st ]: Philadelphia Inquirer
Sun, July 20, 2025
[ Sun, Jul 20th ]: The New Indian Express
[ Sun, Jul 20th ]: ABC
[ Sun, Jul 20th ]: Pacific Daily News
[ Sun, Jul 20th ]: The Cool Down
[ Sun, Jul 20th ]: New Hampshire Union Leader
[ Sun, Jul 20th ]: reuters.com
[ Sun, Jul 20th ]: Chowhound
[ Sun, Jul 20th ]: KSNF Joplin
[ Sun, Jul 20th ]: The Atlantic
[ Sun, Jul 20th ]: WFTV
[ Sun, Jul 20th ]: CBS News
[ Sun, Jul 20th ]: The Daily Dot
[ Sun, Jul 20th ]: Backyard Garden Lover
[ Sun, Jul 20th ]: Forbes
[ Sun, Jul 20th ]: The Jerusalem Post Blogs
[ Sun, Jul 20th ]: Impacts
[ Sun, Jul 20th ]: The Citizen
[ Sun, Jul 20th ]: Business Today
Sat, July 19, 2025
[ Sat, Jul 19th ]: WILX-TV
[ Sat, Jul 19th ]: CBS News
[ Sat, Jul 19th ]: thedirect.com
[ Sat, Jul 19th ]: The New Indian Express
[ Sat, Jul 19th ]: Killeen Daily Herald
[ Sat, Jul 19th ]: Sports Illustrated
[ Sat, Jul 19th ]: gizmodo.com
[ Sat, Jul 19th ]: Forbes
[ Sat, Jul 19th ]: ThePrint
[ Sat, Jul 19th ]: Daily Record
[ Sat, Jul 19th ]: The Daily Star
[ Sat, Jul 19th ]: The Raw Story
[ Sat, Jul 19th ]: Salon
[ Sat, Jul 19th ]: The Cool Down
[ Sat, Jul 19th ]: Seeking Alpha
[ Sat, Jul 19th ]: moneycontrol.com
[ Sat, Jul 19th ]: The Motley Fool
[ Sat, Jul 19th ]: The Jerusalem Post Blogs
[ Sat, Jul 19th ]: The Economist
[ Sat, Jul 19th ]: The Hans India
[ Sat, Jul 19th ]: The Boston Globe
Fri, July 18, 2025
[ Fri, Jul 18th ]: Forbes
[ Fri, Jul 18th ]: WDIO
[ Fri, Jul 18th ]: Wyoming News
[ Fri, Jul 18th ]: Sports Illustrated
[ Fri, Jul 18th ]: Tasting Table
[ Fri, Jul 18th ]: yahoo.com
[ Fri, Jul 18th ]: The New York Times
[ Fri, Jul 18th ]: Patch
[ Fri, Jul 18th ]: St. Joseph News-Press, Mo.
[ Fri, Jul 18th ]: London Evening Standard
[ Fri, Jul 18th ]: Action News Jax
[ Fri, Jul 18th ]: HuffPost
[ Fri, Jul 18th ]: Impacts
[ Fri, Jul 18th ]: Seeking Alpha
[ Fri, Jul 18th ]: CBS News
[ Fri, Jul 18th ]: STAT
[ Fri, Jul 18th ]: GamesRadar+
[ Fri, Jul 18th ]: The New Zealand Herald
[ Fri, Jul 18th ]: USA TODAY
[ Fri, Jul 18th ]: The Hill
[ Fri, Jul 18th ]: Futurism
[ Fri, Jul 18th ]: Business Insider
[ Fri, Jul 18th ]: KIRO-TV
[ Fri, Jul 18th ]: moneycontrol.com
[ Fri, Jul 18th ]: BBC
[ Fri, Jul 18th ]: Phys.org
[ Fri, Jul 18th ]: rnz
[ Fri, Jul 18th ]: The New Indian Express
Thu, July 17, 2025
[ Thu, Jul 17th ]: WTVD
[ Thu, Jul 17th ]: Tim Hastings
[ Thu, Jul 17th ]: ABC
[ Thu, Jul 17th ]: Impacts
[ Thu, Jul 17th ]: Ghanaweb.com
[ Thu, Jul 17th ]: Le Monde.fr
[ Thu, Jul 17th ]: Forbes
[ Thu, Jul 17th ]: gizmodo.com
[ Thu, Jul 17th ]: The Boston Globe
[ Thu, Jul 17th ]: thetimes.com
[ Thu, Jul 17th ]: The Globe and Mail
[ Thu, Jul 17th ]: The Daily Signal
[ Thu, Jul 17th ]: Fox Business
[ Thu, Jul 17th ]: deseret
[ Thu, Jul 17th ]: federalnewsnetwork.com
[ Thu, Jul 17th ]: Daily Mail
[ Thu, Jul 17th ]: rnz
[ Thu, Jul 17th ]: Toronto Star
[ Thu, Jul 17th ]: TechSpot
[ Thu, Jul 17th ]: TheWrap
[ Thu, Jul 17th ]: Houston Public Media
[ Thu, Jul 17th ]: The Independent US
[ Thu, Jul 17th ]: London Evening Standard
[ Thu, Jul 17th ]: breitbart.com
[ Thu, Jul 17th ]: The Cool Down
[ Thu, Jul 17th ]: ThePrint
[ Thu, Jul 17th ]: The Independent
[ Thu, Jul 17th ]: The New Zealand Herald
Mon, July 14, 2025
[ Mon, Jul 14th ]: TechRadar
[ Mon, Jul 14th ]: gadgets360
[ Mon, Jul 14th ]: Patch
[ Mon, Jul 14th ]: Hackaday
Sun, July 13, 2025
[ Sun, Jul 13th ]: People
[ Sun, Jul 13th ]: WPXI
[ Sun, Jul 13th ]: BBC
Sat, July 12, 2025
[ Sat, Jul 12th ]: BBC
[ Sat, Jul 12th ]: CNET
[ Sat, Jul 12th ]: YourTango
Fri, July 11, 2025
[ Fri, Jul 11th ]: AZoLifeSciences
[ Fri, Jul 11th ]: AZFamily
[ Fri, Jul 11th ]: Patch
[ Fri, Jul 11th ]: BBC
[ Fri, Jul 11th ]: Forbes
[ Fri, Jul 11th ]: Mashable
[ Fri, Jul 11th ]: People
Thu, July 10, 2025
[ Thu, Jul 10th ]: Observer
[ Thu, Jul 10th ]: MyBroadband
[ Thu, Jul 10th ]: STAT
[ Thu, Jul 10th ]: Forbes
[ Thu, Jul 10th ]: People
[ Thu, Jul 10th ]: sanews
[ Thu, Jul 10th ]: BeverageDaily
[ Thu, Jul 10th ]: devdiscourse
[ Thu, Jul 10th ]: BBC
Wed, July 9, 2025
[ Wed, Jul 09th ]: ABC7
[ Wed, Jul 09th ]: Forbes
[ Wed, Jul 09th ]: STAT
[ Wed, Jul 09th ]: BBC
[ Wed, Jul 09th ]: NPR
[ Wed, Jul 09th ]: Digit
Tue, July 8, 2025
[ Tue, Jul 08th ]: WCHS
[ Tue, Jul 08th ]: Missourinet
[ Tue, Jul 08th ]: Hub
[ Tue, Jul 08th ]: Patch
[ Tue, Jul 08th ]: 13abc
[ Tue, Jul 08th ]: Fortune
[ Tue, Jul 08th ]: TechRadar
[ Tue, Jul 08th ]: BBC
Mon, July 7, 2025
[ Mon, Jul 07th ]: OPB
[ Mon, Jul 07th ]: CNN
[ Mon, Jul 07th ]: Forbes
[ Mon, Jul 07th ]: BBC
Replacing mutated microglia with healthy microglia halts progression of genetic neurological disease in mice and humans
//science-technology.news-articles.net/content/2 .. tic-neurological-disease-in-mice-and-humans.html
Published in Science and Technology on Friday, July 11th 2025 at 17:03 GMT by AZoLifeSciences🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
A groundbreaking study led by Prof. Bo Peng at Fudan University demonstrates that microglia replacement effectively halts the progression of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP),
CSF1R-related leukoencephalopathy is a progressive and devastating condition characterized by the degeneration of white matter in the brain, leading to cognitive decline, motor impairments, and psychiatric symptoms. The disease typically manifests in adulthood and progresses rapidly, often resulting in death within a few years of diagnosis. The underlying cause is a genetic mutation that impairs the function of microglia, which rely on the CSF1R protein for survival and activity. Without functional microglia, the brain accumulates toxic waste and suffers from chronic inflammation, accelerating neuronal damage. Until now, there have been no effective treatments for this condition, leaving patients and families with little hope for slowing or stopping the disease's relentless progression.
The research highlighted in the article focuses on a novel therapeutic approach: microglia replacement via hematopoietic stem cell transplantation (HSCT), commonly known as bone marrow transplantation. In this procedure, a patient receives healthy donor stem cells that can differentiate into various blood and immune cells, including microglia, after being transplanted into the recipient's body. The idea behind this treatment is to repopulate the brain with functional microglia that can perform their protective and maintenance roles, thereby mitigating the damage caused by the mutated cells. The study tested this approach in both preclinical mouse models and a small cohort of human patients, yielding promising results that suggest a potential paradigm shift in how such genetic neurological disorders are managed.
In the preclinical phase, researchers used mice engineered to carry CSF1R mutations mimicking the human disease. These mice exhibited similar neurological symptoms and brain pathology as human patients, including white matter loss and motor deficits. The team performed bone marrow transplants on these mice, introducing healthy donor cells capable of producing functional microglia. Over time, the transplanted cells successfully migrated to the brain, integrated into the neural environment, and replaced the defective microglia. Remarkably, the treated mice showed a significant reduction in disease progression, with improved motor function, reduced inflammation, and preservation of white matter compared to untreated controls. These findings provided a strong proof of concept for the therapeutic potential of microglia replacement in halting the destructive effects of CSF1R mutations.
Encouraged by the success in animal models, the researchers extended their investigation to human patients with CSF1R-related leukoencephalopathy. The clinical study involved a small group of individuals who underwent HSCT. Similar to the mouse experiments, the goal was to replace the dysfunctional microglia with healthy ones derived from donor stem cells. The results were striking: in the treated patients, the progression of neurological symptoms was halted, and in some cases, there were signs of stabilization or even slight improvement in cognitive and motor functions. Brain imaging further confirmed that the loss of white matter, a hallmark of the disease, was significantly slowed or stopped following the transplant. These outcomes represent a major breakthrough, as they demonstrate for the first time that microglia replacement can alter the course of a fatal genetic brain disorder in humans.
The article also delves into the mechanisms behind the success of this therapy. Microglia derived from the transplanted stem cells were shown to engraft in the brain and restore critical functions such as clearing cellular debris, reducing inflammation, and supporting neuronal survival. The researchers noted that the timing of the transplant is crucial; performing the procedure early in the disease course, before irreversible brain damage occurs, maximizes the likelihood of a positive outcome. This observation underscores the importance of early diagnosis and intervention, which could be facilitated by genetic screening for CSF1R mutations in at-risk populations or families with a history of the disease.
Despite the promising results, the article acknowledges several challenges and limitations associated with this treatment. Bone marrow transplantation is a complex and risky procedure that carries significant potential complications, including graft-versus-host disease, infections, and the need for lifelong immunosuppression to prevent rejection of the donor cells. Additionally, the study involved only a small number of patients, and long-term follow-up is necessary to assess the durability of the treatment's effects and any potential late-onset side effects. The researchers also caution that while the therapy halted disease progression, it did not reverse existing brain damage, highlighting the need for complementary strategies to repair or regenerate lost neural tissue.
The implications of this research extend beyond CSF1R-related leukoencephalopathy. Microglia dysfunction is implicated in a wide range of neurological conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The success of microglia replacement in this study raises the possibility that similar approaches could be adapted to treat other disorders where immune dysregulation in the brain plays a central role. The findings also contribute to a growing body of evidence supporting the critical role of microglia in brain health and disease, prompting further investigation into how these cells can be targeted therapeutically.
Looking ahead, the research team plans to conduct larger clinical trials to confirm the efficacy and safety of HSCT for CSF1R-related leukoencephalopathy. They are also exploring ways to optimize the procedure, such as developing less invasive methods for delivering healthy microglia to the brain or using gene-editing technologies like CRISPR to correct the CSF1R mutation directly in a patient's own cells, thereby eliminating the need for donor transplants. Such innovations could make the treatment more accessible and reduce the associated risks.
In conclusion, the study reported in the MSN Health article represents a significant milestone in the fight against fatal neurological diseases. By demonstrating that microglia replacement through bone marrow transplantation can halt the progression of CSF1R-related leukoencephalopathy in both mice and humans, the research offers a glimmer of hope for patients suffering from this devastating condition. While challenges remain, the findings pave the way for further advancements in personalized medicine and neuroimmunology, potentially transforming the landscape of treatment for a wide array of brain disorders. This work exemplifies the power of translational research, bridging the gap between laboratory discoveries and real-world clinical applications, and underscores the importance of continued investment in scientific innovation to address unmet medical needs. (Word count: 1075)
Read the Full AZoLifeSciences Article at:
[ https://www.msn.com/en-gb/health/medical/microglia-replacement-halts-progression-of-fatal-neurological-disease-in-mice-and-humans/ar-AA1IqOIJ ]